1. 679PMeta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer. (23rd October 2018) Authors: Nishikawa, K; Koizumi, W; Tsuburaya, A; Yamanaka, T; Morita, S; Fujitani, K; Akamaru, Y; Shimada, K; Hosaka, H; Nakayama, N; Miyashita, Y; Tsujinaka, T; Sakamoto, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 685PRelation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer. (23rd October 2018) Authors: Takeuchi, M; Ichikawa, W; Shitara, K; Sunakawa, Y; Oba, K; Koizumi, W; Sakata, Y; Furukawa, H; Takeuchi, M; Fujii, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 713PAnalysis of BRCAness with MLPA in pancreatic ductal adenocarcinoma patients using FFPE sample obtained via EUS-FNAB. (23rd October 2018) Authors: Okuwaki, K; Imaizumi, H; Masutani, H; Yoshida, T; Kida, M; Iwai, T; Yamauchi, H; Kaneko, T; Hasegawa, R; Miyata, E; Adachi, K; Tadehara, M; Koizumi, W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 721PA phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer. (23rd October 2018) Authors: Miyata, E; Okuwaki, K; Imaizumi, H; Kida, M; Iwai, T; Yamauchi, H; Kaneko, T; Hasegawa, R; Adachi, K; Tadehara, M; Koizumi, W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P509 Long-term outcomes of adalimumab in patients with Crohn's disease: Can a doubled dose of adalimumab improve outcomes?. (25th January 2019) Authors: Kanazawa, J; Yokoyama, K; Matsumoto, Y; Kawagishi, K; Mukae, M; Kubota, M; Kobayashi, K; Koizumi, W Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S367 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗